Cannabis Investments

Chinese textile industry consists of cotton and chemical fiber weaving , printing & dyeing and finishing, wool weaving, dyeing and finishing, hemp weaving, silk weaving and finish machining, as well as the production of cotton, chemical fiber, wool, hemp and silk products. It has to be pointed out that Chinese textile industry does not include clothing manufacturing.
Chinese textile industry has been in recovery from the downturn of January and February of 2009. A number of indexes in 2009Q2 indicate that Chinese textile industry has begun to recover. From January to May of 2009, the sales revenue of Chinese textile industry was RMB 781.296 billion, rising by 5.16% YOY. At the end of May 2009, the asset in Chinese textile industry was RMB 1.468828 trillion, increasing by 7.9% YOY; the number of enterprises was 31,459, rising by 2,944 YOY.
At the end of May 2009, the sales revenue per capita of Chinese textile industry was RMB 133,400, rising by RMB 7,800 YOY. The asset per capita was RMB 250,800, increasing by 20,000 YOY. The sales revenue per company was RMB 24.8354 million, reducing by RMB 1.9105 million YOY. The asset per company was RMB 46.6902 million, decreasing by RMB 2.4643 million YOY.
Chinese government has strengthened the investment since 2009. Thus the fixed asset investment in the textile industry sees slight recovery. In 2009H1, the fixed asset investment in Chinese textile industry was RMB 78.081 billion, rising by 7% YOY. From January to May, the quantity of projects with over RMB 5 million (included) fixed asset investment was 5,766, rising by 2.98% YOY.
In 2009H1, the output of Chinese yarn was 10.962 million tons, rising by 9.40% YOY. The outputs of Shandong, Jiangsu, Henan, Zhejiang and Fujian ranked among the Top 5. The aggregate output of the five regions took up 73.75% of that in China.
In 2009H1, the output of Chinese cloth was 25.8 billion meters, rising by 0.20% YOY. The outputs of Zhejiang, Shandong, Jiangsu, Hubei and Hebei ranked among the Top 5. The aggregate production of the five regions accounted for 75.66% of that in China.
In 2009H1, the output of Chinese cotton cloth was 14.58 billion meters, increasing by 1.70% YOY. The outputs of Shandong, Jiangsu, Hubei, Hebei and Henan ranked among the Top 5. The aggregate production of the five regions took up 76.67% of that in China.
In 2009H1, the output of Chinese pure chemical fiber cloth was 7.04 billion meters, decreasing by 0.4% YOY. The outputs of Zhejiang, Jiangsu, Fujian, Shandong and Guangdong ranked among the Top 5. The aggregate production of the five regions took up 94.20% of that in China.
In 2009H1, the output of Chinese printing and dyeing cloth was 24.227 billion meters, rising by 3.38% YOY. The outputs of Zhejiang, Jiangsu, Guangdong, Shandong and Fujian ranked among the Top 5. The aggregate production of the five regions accounted for 89.84% of that in China.
In 2009H1, the output of Chinese cord fabric was 227,700 tons, increasing by 0.37% YOY. The outputs of Jiangsu, Shandong, Zhejiang, Henan and Anhui ranked among the Top 5. The aggregate production of the five regions took up 95% of that in China.
In 2009H1, the output of Chinese yarn-dyed fabric was 919.5949 million meters, rising by 9.36% YOY. The outputs of Jiangsu, Shandong, Zhejiang, Hunan and Guangdong ranked among the Top 5. The aggregate production of the five regions took up 84.90% of that in China.

For more information please contact :

http://www.aarkstore.com/reports/Research-Report-on-Chinese-Textile-Industry-2008-2009-32797.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise
Contact: Neel
Email: press@aarkstore.com
http://www.aarkstore.com

Aradigm Corporation – Medical Equipment – Deals and Alliances Profile is an essential source for company data and information. The profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company’s major recent financial deals.

Aradigm Corporation (Aradigm) is a specialty pharmaceutical company engaged in the development and commercialization of drugs delivered by inhalation for treating severe respiratory diseases by pulmonologists. It has developed pulmonary drug delivery system, AERx Essence and AERx Strip Technology for the delivery of drugs to the target. The company’s current pipeline comprises of products used for treating cystic fibrosis, inhalation anthrax and bronchiectasis. Additionally, it plans to use its technology for tobacco smoking cessation therapy. Aradigm is headquartered at Hayward in California, the US.

And More inside the report…

Recent Developments

Aug 06, 2009: Aradigm Reports Net Loss Of $4.6 Million In Q2 2009
Jul 23, 2009: Aradigm Gets FDA Clearance For Phase IIb Ciprofloxacin Trial
May 12, 2009: Aradigm Posts Net Loss Of $5.2 Million For Q1 2009

Scope

- Provides key company information for business intelligence needs
- Gives information on the company’s major recent financial deals including mergers & acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.

Reasons to buy

- A quick “one-stop-shop” to understand the company.
- Support sales activities by understanding your customers’ businesses.
- Qualify prospective partners and suppliers.
- Understand and respond to your competitors’ business structure, strategy and prospects through.
- Understanding the key deals which have shaped the company.

Company Mentioned
The following companies are the major competitors of Aradigm Corporation:
Bayer HealthCare AG
Nektar Therapeutics
Pfizer Inc.

For more information, please visit:

http://www.aarkstore.com/reports/Aradigm-Corporation-Medical-Equipment-Deals-and-Alliances-Profile-38707.html

Or email us at press@aarkstore.com or call +919272852585

The industry analysis specialist’s new report, “Neuropathic Pain – Drug Pipeline Analysis and Market Forecasts to 2015″ is an essential source of information and analysis on the global neuropathic pain market. The report identifies the key trends shaping and driving the global neuropathic pain market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global neuropathic pain sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.

Estimated the global neuropathic pain market to be valued at $4.8 billion in 2008. It is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 4.3% from $4.8 billion in 2008 to $6.5 billion in 2015. This growth will be supported by the increase in the aging population, increased treatment seeking behavior, increased uptake of the current products. Diagnosis rate remains as one of the barriers for the growth of the market. The available treatment options are moderately successful in meeting the market demand. There is still a need for better therapy and there exists the unmet need. There exists a market potential for any new entrant that will cater these unmet needs. There is enormous opportunity for any drug that would offer better or retain the efficacy provided by the current players with increased safety than the current products.

Analyzed that there are over 111 molecules in various stages of the pipeline. Vimpat, Qutenza, Fentora are some of the pipeline candidates in the regulatory filing stage for approval. The late stage pipeline includes some of the promising molecules like Ralfinamide, NP-1, Sativex. These drugs may retain the similar efficacy and offer better safety and may benefit the patient population who cannot endure the available drugs. The newer therapies may intensify the existing competition and there seems to be a possibility of price war.

Scope of the Report

The scope of the report includes:

Annualized global neuropathic pain market revenues data from 2006 to 2008, forecast forward for 7 years to 2015.

Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes opioid receptor agonists, cannabinoid receptor modulators, NMDA antagonists, protein kinase inhibitors, ion channel targetters, serotonin norepinephrine reuptake inhibitors, adenosine agonists, cytokine modulators, AMPA antagonists, nicotinic receptor agonists, TRPV1 receptor agonists, selective subtype sodium channel antagonists, iNOS/nNOS dual inhibitors.

Analysis of the current and future market competition in the global neuropathic pain market. Key future market players covered are NeurogesX, Cephalon Inc., UCB S.A., Newron Pharmaceuticals, EpiCept Corporation, GW Pharmaceuticals, Johnson & Johnson, Avanir pharmaceuticals, GlaxoSmithKline plc., AstraZeneca.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with neuropathic pain.

Reasons to Buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global neuropathic pain market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global neuropathic pain market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next big thing in the global neuropathic pain market landscape? – Identify, understand and capitalize.

For more information,please visit:

http://www.aarkstore.com/reports/Neuropathic-Pain-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015-40530.html

Summary

It is the industry analysis specialist’s new report, “Dyslipidemia – Drug Pipeline Analysis and Market Forecasts to 2016″” is an essential source of information and analysis on the global dyslipidemia market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global dyslipidemia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global dyslipidemia sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by its team of industry experts.

Scope

The scope of the report includes:
– Annualized global dyslipidemia market revenue data from 2001 to 2009, forecast for seven years to 2016.
– Geographies covered in this report are the US, the UK, Italy, Spain, Germany, France, and Japan.
– Pipeline analysis data split across different phases, mechanism of action being developed and emerging trends. The key classes of mechanism of action include combination therapies, CETP inhibitors, MTP inhibitors, PPAR agonists, thyroid hormone receptor modulators, gene therapies, nicotinic acid receptor agonists, AMPK modulators, enzyme inhibitors, cholesterol absorption inhibitors, farsenyl X receptor agonists, prostacyclin release stimulators, CB1 receptor agonists, A1 adenosine receptor agonists and omega-3 fatty acid derivatives.
– Analysis of the current and future market competition in the global dyslipidemia market. The key future market players covered are AstraZeneca PLC, Abbott Laboratories, Merck & Co., GenFit, Aegerion Pharmaceuticals, Inc., Amarin Corporation Plc, Pfizer Inc., and F. Hoffman-La Roche.
– Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
– The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future dyslipidemia market.

For more information, please visit:

http://www.aarkstore.com/reports/Dyslipidemia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-37971.html

Or email us at press@aarkstore.com or call +919272852585

Aarkstore Enterprise

Tel : +912227453309

Mobile No: +919272852585

Email : contact@aarkstore.com

Website : http://www.aarkstore.com

Blog: http://blogs.aarkstore.com/

Follow us on twitter: http://twitter.com/aarkstoredotcom

Description

The industry analysis specialist’s new report, “Neuropathic Pain – Drug Pipeline Analysis and Market Forecasts to 2015″ is an essential source of information and analysis on the global neuropathic pain market. The report identifies the key trends shaping and driving the global neuropathic pain market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global neuropathic pain sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.

Estimated the global neuropathic pain market to be valued at $4.8 billion in 2008. It is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 4.3% from $4.8 billion in 2008 to $6.5 billion in 2015. This growth will be supported by the increase in the aging population, increased treatment seeking behavior, increased uptake of the current products. Diagnosis rate remains as one of the barriers for the growth of the market. The available treatment options are moderately successful in meeting the market demand. There is still a need for better therapy and there exists the unmet need. There exists a market potential for any new entrant that will cater these unmet needs. There is enormous opportunity for any drug that would offer better or retain the efficacy provided by the current players with increased safety than the current products.

Analyzed that there are over 111 molecules in various stages of the pipeline. Vimpat, Qutenza, Fentora are some of the pipeline candidates in the regulatory filing stage for approval. The late stage pipeline includes some of the promising molecules like Ralfinamide, NP-1, Sativex. These drugs may retain the similar efficacy and offer better safety and may benefit the patient population who cannot endure the available drugs. The newer therapies may intensify the existing competition and there seems to be a possibility of price war.

Scope of the Report

The scope of the report includes:

Annualized global neuropathic pain market revenues data from 2006 to 2008, forecast forward for 7 years to 2015.

Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes opioid receptor agonists, cannabinoid receptor modulators, NMDA antagonists, protein kinase inhibitors, ion channel targetters, serotonin norepinephrine reuptake inhibitors, adenosine agonists, cytokine modulators, AMPA antagonists, nicotinic receptor agonists, TRPV1 receptor agonists, selective subtype sodium channel antagonists, iNOS/nNOS dual inhibitors.

Analysis of the current and future market competition in the global neuropathic pain market. Key future market players covered are NeurogesX, Cephalon Inc., UCB S.A., Newron Pharmaceuticals, EpiCept Corporation, GW Pharmaceuticals, Johnson & Johnson, Avanir pharmaceuticals, GlaxoSmithKline plc., AstraZeneca.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with neuropathic pain.

For more information, please visit:

http://www.aarkstore.com/reports/Neuropathic-Pain-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015-40530.html

Or email us at press@aarkstore.com or call +919272852585

Aarkstore Enterprise

Tel : +912227453309

Mobile No: +919272852585

Email : contact@aarkstore.com

Website : http://www.aarkstore.com

Blog: http://blogs.aarkstore.com/

Follow us on twitter: http://twitter.com/aarkstoredotcom